文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛儿科与产科急症

气道压力释放通气在儿童急性呼吸窘迫综合征中的随机对照试验

Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01
一句话结论儿童ARDS以APRV作为初始通气策略时,28天全因死亡率53.8% vs 对照26.9%(RR 2.0,95%CI 0.97-4.1),因干预组死亡率更高提前终止。

该开放标签、平行设计随机对照试验在15张床ICU纳入1月龄至12岁、符合改良柏林定义的儿童ARDS,排除气漏、颅内压增高、自主呼吸努力差、慢性肺病及ARDS诊断超过24小时或机械通气超过72小时者。比较APRV与常规低潮气量通气(LoTV)对无呼吸机天数的影响,入组50%(52例)时因干预组死亡率更高而提前终止。无呼吸机天数两组差异无统计学意义(P=0.23);28天全因死亡率APRV组53.8% vs 对照组26.9%(RR 2.0,95%CI 0.97-4.1;Fisher精确P=0.089),多变量校正死亡RR 2.02(95%CI 0.99-4.12;P=0.05)。干预组平均气道压更高、自主呼吸更多、氧合改善更早。

要点

  • 儿童ARDS以APRV作为初始通气策略,28天全因死亡率53.8%(14/26)vs LoTV 26.9%(7/26),RR 2.0(95%CI 0.97-4.1),试验因干预组死亡率更高在入组50%时提前终止。
  • 无呼吸机天数APRV组与LoTV组差异无统计学意义(P=0.23)。
  • 多变量校正后APRV相对LoTV的死亡RR为2.02(95%CI 0.99-4.12;P=0.05)。
  • APRV组平均气道压更高、自主呼吸更多、氧合改善更早,但未转化为无呼吸机天数获益。
  • 作者结论:APRV作为儿童ARDS初始通气策略与常规LoTV相比,死亡率有升高趋势;解读结果时应考虑研究局限性。

适用人群与场景

  • 1月龄至12岁、符合改良柏林定义的儿童ARDS,收入15张床ICU。
  • 排除气漏、颅内压增高、自主呼吸努力差、慢性肺病、ARDS诊断超过24小时或机械通气超过72小时的患儿。

诊断标准与关键阈值

  • 纳入标准为符合改良柏林定义的儿童ARDS。

研究设计与关键结果

  • 开放标签、平行设计随机对照试验,15张床ICU,计划入组50%时进行期中分析,入组52例后因干预组死亡率更高而提前终止。
  • 主要终点无呼吸机天数两组差异无统计学意义(P=0.23)。
  • 28天全因死亡率APRV组53.8% vs 对照组26.9%,RR 2.0(95%CI 0.97-4.1),Fisher精确P=0.089。
  • 多变量校正后APRV相对LoTV死亡RR 2.02(95%CI 0.99-4.12;P=0.05)。
  • APRV组平均气道压更高、自主呼吸更多、氧合改善更早。
  • 随访至入组后180天或死亡(以较早者为准)。

证据类型、等级与局限

  • 证据类型:随机对照试验(开放标签、平行设计)。
  • 试验注册:ClinicalTrials.gov(NCT02167698)和印度临床试验注册中心(CTRI/2014/06/004677)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在儿童ARDS中,以APRV作为初始通气策略与常规LoTV相比,28天全因死亡率呈升高趋势(53.8% vs 26.9%,RR 2.0,95%CI 0.97-4.1),该试验因干预组死亡率更高而提前终止。
  • 作者认为,APRV作为儿童ARDS初始通气策略与常规LoTV相比死亡率有升高趋势,解读结果时应考虑研究局限性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Although case series describe benefits of airway pressure release ventilation (APRV), this mode of ventilation has not been evaluated against the conventional low-tidal volume ventilation (LoTV) in children with acute respiratory distress syndrome (ARDS).

OBJECTIVES: To compare the effect of APRV and conventional LoTV on ventilator-free days in children with ARDS.

METHODS: This open-label, parallel-design randomized controlled trial was conducted in a 15-bed ICU. Children aged 1 month to 12 years satisfying the modified Berlin definition were included. We excluded children with air leaks, increased intracranial pressure, poor spontaneous breathing efforts, chronic lung disease, and beyond 24 hours of ARDS diagnosis or 72 hours of ventilation. Children were randomized using unstratified, variable-sized block technique. A priori interim analysis was planned at 50% enrollment. All enrolled children were followed up until 180 days after enrollment or death, whichever was earlier.

MEASUREMENTS AND MAIN RESULTS: The trial was terminated after 50% enrollment (52 children) when analysis revealed higher mortality in the intervention arm. Ventilator-free days were statistically similar in both arms (P = 0.23). The 28-day all-cause mortality was 53.8% in APRV as compared with 26.9% among control subjects (risk ratio, 2.0; 95% confidence interval, 0.97-4.1; Fisher exact P = 0.089). The multivariate-adjusted risk ratio of death for APRV compared with LoTV was 2.02 (95% confidence interval, 0.99-4.12; P = 0.05). Higher mean airway pressures, greater spontaneous breathing, and early improvement in oxygenation were seen in the intervention arm.

CONCLUSIONS: APRV, as a primary ventilation strategy in children with ARDS, was associated with a trend toward higher mortality compared with the conventional LoTV. Limitations should be considered while interpreting these results. Clinical trial registered with www.clinicaltrials.gov (NCT02167698) and Clinical Trials Registry of India (CTRI/2014/06/004677).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, et al. Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018. PMID: 29641221. doi:10.1164/rccm.201705-0989OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。